Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

33.02 +1.04 (+3.24%)

Streaming Delayed Price Updated: 10:45 AM EST, Jan 14, 2026 Add to My Watchlist

Price and Volume

Volume	118,241
Open	31.99
Bid (Size)	32.98 (200)
Ask (Size)	33.08 (200)
Prev. Close	31.99
Today's Range	31.69 - 33.09
52wk Range	9.900 - 34.04
Shares Outstanding	9,587,155
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Prepares for Transformational 2026

January 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Performance

YTD	+7.6%	+7.6%
1 Month	-0.0%	-0.0%
3 Month	+58.9%	+58.9%
6 Month	+103.1%	+103.1%
1 Year	+85.8%	+85.8%

More News

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Via The Motley Fool

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

December 22, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗

December 18, 2025

Via Chartmill

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

November 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

October 21, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering

October 21, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts ↗

October 21, 2025

Via Benzinga

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

October 20, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

Via Benzinga

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

September 15, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results ↗

August 07, 2025

Via Benzinga

Viridian (VRDN) Q2 Net Loss Widens 55% ↗

August 06, 2025

Via The Motley Fool

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

August 06, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 04, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

July 30, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?

Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?

The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market

What is the current price of Viridian Therapeutics, Inc. - Common Stock?

The current price of Viridian Therapeutics, Inc. - Common Stock is 33.02

When was Viridian Therapeutics, Inc. - Common Stock last traded?

The last trade of Viridian Therapeutics, Inc. - Common Stock was at 01/14/26 10:45 AM ET

What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?

The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 316.62M

How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?

Viridian Therapeutics, Inc. - Common Stock has 317M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.